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ABSTRACT 
IN VITRO SCREENING FOR SMALL-MOLECULE KINASE INHIBITORS OF TESTIS-SPECIFIC 
SERINE KINASE 1 (TSSK1), A POTENTIAL TARGET FOR MALE CONTRACEPTION 
SEPTEMBER 2015 
JULIE K. MAJKA, B.S. VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY 
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST 
Directed by: Dr. Ana Maria Salicioni 
Despite the availability of a range of contraceptive methods, over 50% of 
pregnancies are unintended worldwide (~1,000,000/day). Male contraception remains an 
important area of research. Recent acceptability studies indicate that a high percentage of 
men would be willing to use a male contraceptive pill. Several non-hormonal targets for a 
male-based contraceptive pill have been brought to light recently including the testis-
specific serine kinase (TSSK) family, which belongs to the AMPK kinase branch in the 
CAMK group. The finding that TSSK family members are postmeiotically expressed in 
male germ cells, together with the infertile phenotype found in both Tssk1/2 and Tssk6 
mouse knock-out models, has led to the proposal that TSSKs play an important role in 
sperm function, making them excellent targets for drug design of novel male 
contraceptives.  
This research is aimed to the identification of potent, specific inhibitors for 
TSSK1 activity for the development of novel male contraceptive pills through the use of 
mice as an experimental model. Our hypothesis is that a single kinase inhibitor can 
specifically inhibit TSSK’s kinase activity without interfering with other sperm functions, 
or other tissue types. In this study, we have assessed the enzyme properties of 
vii 
recombinant human TSSK1 by application of a homogeneous, non-radioactive enzyme 
activity assay and mid-throughput screening of kinase inhibitors that block TSSK1 
activity. Some of these inhibitors have proven to greatly reduce the activity of TSSK1 
overall, but lack the specificity desired to be plausible for drug design.  
In parallel, our efforts are directed towards developing a functional in vivo assay 
using both CD1 and acrosin-GFP-transgenic mice (expressing Acr-GFP in the acrosome) 
based on our finding that TSSK1 is localized in the sperm acrosome, which points to a 
potential role of TSSKs in sperm acrosome reaction.  
 The anticipated outcome of this research is to ultimately develop a reversible, 
non-hormonal male contraceptive. Our findings may also set the basis for studies on 
human sperm function towards a better understanding of male reproductive physiology 
and mechanisms of male infertility.
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Since the 1950’s, women have been the target demographic for developing 
contraceptive products, placing the majority of the fertility decisions with the female. 
However, men play an undeniable role in procreation, and deserve an equal opportunity 
for contraceptive options.  
Nearly 37-50% of pregnancies worldwide are unintended (Mosher, Jones et al. 
2012), which demonstrates the current need for additional forms of contraception (Fig. 
1). Men only have three options in terms of pregnancy prevention: condoms, withdrawal, 
or vasectomy. Condoms are easily reversed and 98% effective if used correctly, but has a 
failure rate of up to 82%, according to the Center for Disease Control. Withdrawal prior 
to ejaculation is a non-permanent option, but only ~72% effective. The final option is a 
vasectomy, which is nearly 100% effective, but is a surgical procedure that includes the 
ligation of the vas deferens, thus preventing ejaculation of spermatozoa. However, this 
procedure is not easily reversed (Control 2015). Evidently, there is a serious lack of male 
contraceptive options available; however there are several potential sources for 
alternative contraceptive development and research. Currently there are several targets 
being studied worldwide that are potential targets for male contraceptives. One such 
study is of a physical barrier known as “Reversible inhibition of sperm under guidance 
(RISUG)” in India, where it was developed, or as Vasalgel in the United States (Lohiya, 
Alam et al. 2014). This polymer is injected directly into the vas deferens and can later be 
reversed by injecting a dissolving agent. RISUG is currently in Phase III trials in India. 
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Another area of interest for targets of male contraceptives is focused on hormonal targets; 
gestagens produced from either testosterone or progesterone derivatives, are being 
investigated, some having reached clinical trials (Nieschlag 2010, Dorman and Bishai 
2012). Other targets are non-hormonal: epididymal proteins, opioids, miRNAs, plant 
extracts, heat/ultrasound treatment, among others (Garside 2013, Kogan and Wald 2014, 
Murdoch and Goldberg 2014). In particular, one such area under active investigation is 
on testis-specific protein kinases, which is the main focus of research in our laboratory.  
Because sperm undergoes a number of changes between ejaculation and 
fertilization, sperm-specific proteins are ideal targets for contraception. When the sperm 
enters the female reproductive tract, it undergoes a process known as “capacitation.” 
Capacitation includes the acquisition of hyperactive motility (Yanagimachi 1981, Suarez, 
Katz et al. 1983) and the ability to experience the acrosome reaction – an exocytotic 
process that allows penetration of the zona pellucida by the sperm cell (Dan 1952). These 
activation-type steps and physiological changes to the sperm are required for oocyte 
fertilization (Chang 1951, Visconti 2009). Figure 3 shows the accepted model on the 
series of biochemical steps which sperm undergoes during capacitation.  
Protein kinases are found throughout humans and animals; their role lies in cell 
regulation. Typically kinases phosphorylate some aspect of a protein. This 
phosphorylation allows the protein kinase to orchestrate numerous cellular functions, 
protein localization, and cell cycle activities. Kinases are protein-specific so they are 
grouped in families; these families share similar sequences and catalytic domains. One 
subgroup of kinases are those that phosphorylate serine and threonine residues 
((Manning, Whyte et al. 2002) and references therein).  
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The Testis-Specific Serine Kinases (TSSKs) belong to a family of kinases with a 
major role proposed in spermatogenesis (Li, Sosnik et al. 2011). This group of 
serine/threonine kinases is part of the 5’ adenosine-monophosphate activated kinase 
(AMPK) branch in the calcium/calmodulin-dependent kinase (CAMK) group (Fig. 2) and 
lends itself to potentially be a non-hormonal target for a male contraceptive pill via 
inhibition of TSSKs (Salicioni 2012). The benefit of these kinases lies within its name: 
testis-specific. Being specific to the testis allows for research in this particular area 
without much concern for the effect of a kinase inhibitor on other tissues. It is known that 
members of the TSSK family are expressed postmeiotically in mature male germ cells 
(Hao, Jha et al. 2004, Li, Sosnik et al. 2011). It has been shown that TSSK1 is localized 
to the head, specifically the acrosomal region, of the mature sperm, as well as the 
flagellum (Li, Sosnik et al. 2011) (Fig. 4). Lastly, It is also known that the TSSK1/2 
knockout (Xu, Hao et al. 2008, Shang, Baarends et al. 2010) and the TSSK6 knockout 
(Spiridonov, Wong et al. 2005) phenotypes render male mice infertile (Xu, Hao et al. 
2008, Shang, Baarends et al. 2010), suggesting that the TSSK family plays a major role 
in male fertility and could be a target for specific inhibitors leading to a male 
contraceptive pill (Li, Sosnik et al. 2011).  
One of our lab’s research goals is to find a specific inhibitor of TSSKs that would 
suppress their activity to a level that would render the kinase ineffective. Knowledge of 
TSSKs’ position on the murine and human kinome led to the notion that an AMPK 
inhibitor may be suitable for the role of suppressing TSSK activity. AMPK is a 
heterotrimeric protein kinase comprised of three subunits: α, β, and γ, with α being the 
catalytic subunit (Hardie 2015). As discussed previously, TSSKs are found on the AMPK 
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branch of the kinome. AMPK acts as an ATP sensor within the cell, maintaining energy 
balance via stimulation of catabolic pathways and inhibition of anabolic pathways (Liu, 
Chhipa et al. 2014, Nguyen, Alves et al. 2014). There exists an AMPK inhibitor, 
Compound C (CC), –also known as “dorsomorphin” and/or “BML-275”– that is 
selective, and is a competitive inhibitor at ATP-binding sites (Nguyen, Alves et al. 2014). 
Based on the literature, especially Nguyen et al (2014) and de Llera et al (2012) (Hurtado 
de Llera, Martin-Hidalgo et al. 2012), it has been proposed that CC has a significant 
effect on sperm in a number of other species, including humans. 
Our research looks into the biochemical regulation of mouse TSSKs and its role 
in the capacitation process and therefore, their potential for a non-hormonal target for 
contraception. By using a variety of experimental conditions, the objective of our current 
investigation is to find a selective inhibitor of TSSKs, using TSSK1 as a model kinase, 
which can be used in an easily reversible, oral contraceptive for men, thus providing 
another option for men to choose from when considering contraceptive alternatives. 
1.2 Materials & Methods 
1.2.1 Aim 1 Materials 
1.2.1.1 ADP-Glo™ kit 
The ADP-Glo™ kit was purchased from Promega Corporation (Madison, WI) 
and includes Ultra Pure ATP and ADP, Glo reagent, and the detection agent 
(luciferase/luciferin). 96- and 384-well plates were purchased from VWR Scientific 
(Radnor, PA). All reactions were performed in a kinase buffer consisting of a Tris-HCl 
mixture (Trizma base from Sigma-Aldrich, St. Louis, MO and HCl from Fisher, 
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Waltham, MA), at a pH of 7.4, MgCl2 (Sigma-Aldrich), bovine serum albumin (BSA) 
from Sigma-Aldrich, and MilliQ water.  
1.2.1.2 Kinases and Substrates 
Human recombinant TSSK1 was purchased through Invitrogen (Carlsbad, CA) 
and was the kinase used for all kinase assays. Two substrates were used for the 
standardization of the kinase assay: myelin basic protein peptide (MBPp) and AMARA. 
MBPp was purchased through Sigma-Aldrich, and the AMARA substrate was purchased 
via AnaSpec, Inc., (Fremont, CA). 
1.2.1.3 Inhibitors 
To observe TSSK1 inhibition, several inhibitors were used: Staurosporine, H7, 
NMPP1, Roscovitine, Kenpaullone, SU6656, H89, SKI 606, and Compound C. 
Staurosporine and Roscovitine were purchased from LC Labs (Woburn, MA). NMPP1, 
Kenpaullone, H89, and SKI 606 were purchased from Cayman Chemical (Ann Arbor, 
MI). H7 was purchased from Tocris Bioscience (Bristol, UK). SU6656 was purchased 
from Sigma-Aldrich. Compound C was purchased from Enzo Life Sciences 
(Farmingdale, NY). DMSO was required for preparation of stock solutions (typically 
10mM) of several of these inhibitors, including Compound C; thus DMSO (at the 
corresponding percentage in final solutions) was used as the vehicle control. 
1.2.1.4 Equipment and Data Analysis 
Incubation of kinase reactions was performed in an Eppendorf Thermomixer® R 
at 37°C. Following completion of the assay, the plate was read in a POLARstar Omega 
plate reader by BMG Labtech. The POLARstar machine was set to read plates at an 
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interval of 0.10 seconds at a gain of 2500-3600 at 80%. Data was analyzed using both 
Microsoft Excel and SigmaPlot (by Systat Software Inc.).  
1.2.2 Aim 1 Methods 
1.2.2.1 Kinase Assay 
The initial step in running the assay was preparing the buffer; to do so, Tris-HCl 
at 40mM and pH of 7.4 was combined with 20mM MgCl2, BSA at 0.1mg/ml, and MilliQ 
water. This buffer was used throughout the assay to prepare the other reagents. The ATP 
was prepared at varying concentrations between 0-1mM using the buffer to dilute the 
ATP as needed. The substrates (AMARA and MBPp) were prepared at concentrations 
ranging from 0-100μM using buffer as a reconstitution agent. The kinase (hrTSSK1) was 
prepared at different concentrations ranging from 0-300ng in the previously described 
buffer. In some cases, the experimental reagent was prepared by using serial dilution.  
In the 96-well plate assays, we decided to have a total quantity of 25μl per kinase 
reaction. In 384-well plate assays, only a total of 5μl of reagents were included in each 
well.  
When conducting an assay, the reagents were prepared and put into the 
appropriately sized well plate at a ratio of 1:1:1:2 (buffer, ATP, substrate, kinase, 
respectively, and +/- inhibitor), and incubated at 37°C for 30 minutes in the Eppendorf 
Thermomixer® R. Next, the Glo reagent was added; the ratio was 1:1:2, indicating 
amounts for the reaction, Glo reagent, and detection agent, respectively. For a 96-well 
plate reaction that carried a volume of 25μl of kinase reaction, 25μl of Glo reagent was 
added to the reaction following the incubation period. The reaction was allowed to 
proceed at room temperature for 40 minutes. After this second incubation, 50μl of 
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detection reagent was added to each reaction and incubated away from light for 60 
minutes at room temperature. The plate was then read in the POLARstar Omega plate 
reader, which generated the number of relative luminescence units (RLUs), a direct 
indicator of ADP production and, thus, of kinase activity. Figure 5 provides a principle of 
the ADP-Glo™ kinase reaction and detection, and a summary of the reactions that 
occurred during this process. 
1.2.3 Aim 2 Materials 
1.2.3.1 Animals 
CD1 retired male breeder mice were purchased from Charles River Laboratories 
(Wilmington, MA). Transgenic Acr-GFP male and female mice were donated from Dr. 
G. Gerton (UPenn, Philadelphia, PA), who had originally obtained them from M. Okabe 
(Okabe, Ikawa et al. 1997, Ikawa, Yamada et al. 1999, Nakanishi, Ikawa et al. 1999, 
Ventela, Mulari et al. 2000, Hasuwa, Muro et al. 2010). All mice were maintained and 
housed for up to two weeks in a monitored facility at the University of Massachusetts, 
Amherst; all animal protocols were reviewed and approved by the University of 
Massachusetts Institutional Animal Care and Use Committee. 
1.2.3.2 Media and Inhibitors 
Protein extraction of mouse sperm cells was performed in modified Toyoda–
Yokoyama–Hosi (mTYH) media (Tateno, Krapf et al. 2013) prepared and stored at 4°C 
within one month of use. The media was prepared with the following components (in 
millimolar concentrations, from Sigma-Aldrich): 119.37 NaCl, 4.7 KCl, 1.71 
CaCl22H2O, 1.2 KH2PO4, 1.2 MgSO47H2O, 20 Hepes, 5.56 glucose, 0.51 sodium 
pyruvate, 10μg/mL gentamicin, and 0.0006% phenol red. To prepare capacitating (Cap) 
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media using mTYH, 10mg/ml of BSA (Sigma-Aldrich) and 30mM of HCO-3 (Sigma-
Aldrich) was added to the media on the day of the assay. Noncapacitating (NC) media did 
not have the BSA or HCO-3 additives. The pH of the media was adjusted using 
200mg/mL NaOH (Sigma-Aldrich) to pH 7.2-7.4 (typically falling between 7.32-7.38). 
M2 media was purchased from Sigma-Aldrich and used during IVF.  
The AMPK inhibitor Compound C was prepared in DMSO at 10mM from Enzo 
Life Sciences (Farmingdale, NY) and was used during subsequent capacitation 
experiments. 
1.2.3.3 Western Blot and Immunoprecipitation Assay 
Reagents used in sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE) and the protein molecular weight marker were purchased from 
Bio-Rad (Hercules, CA). The polyvinylidene difluoride (PVDF) membrane was 
purchased from EMD Millipore (Billerica, MA). BioMax Light film was purchased from 
Carestream Health Care, Inc./Kodak, Rochester, NY. Fish skin gelatin was purchased 
from Sigma-Aldrich. Antibodies were purchased as follows: AMPKα poly- and 
monoclonal, and anti-PKA from Cell Signaling (Danvers, MA), monoclonal anti-PY 
from EMD Millipore (Billerica, MA), and anti-tubulin clone E7 from DSHB. Secondary 
antibodies (anti-mouse IgG, anti-rabbit IgG, HRP and High + Light chain) were 
purchased from Jackson ImmunoResearch (West Grove, PA). The inhibitors used to 
create RIPA+ and PBS+ included NaVO4 (1mM from Sigma), βGP (40mM from Sigma), 
and 50X protease inhibitor from Roche. 
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C2C12 murine lysates were purchased from Cell Signaling. 293T cells were 
grown in-lab in a monolayer and pelleted prior to lysis. Magnetic A-beads and G-beads 
were purchased from Millipore (Billerica, MA).  
1.2.3.4 Sperm Cell Viability Assay 
The Live/Dead® Sperm Viability Kit was purchased from Life Technologies 
(Carlsbad, CA) and was prepared as indicated in the manufacturer’s protocol. A HEPES-
buffered saline solution was prepared and contained: 10mM HEPES (from Fisher), 
150mM NaCl (from Sigma), and 10% BSA at a pH of 7.4. 
1.2.3.5 Computer-Assisted Sperm Analysis (CASA) 
Mouse sperm cells were loaded into a single side of a 2-chambered 100-micron 
slide (Leja, Netherlands). The slide was read using an Olympus CX41 microscope, and 
sperm motility data captured by HTR motility software (Equine – Version 14 Build 008 
programed for mouse sperm by Hamilton-Thorne/Pyramid Technical Consultants, Inc.). 
Data acquisition was programmed at the following settings: Image capture at 60 
frames/second at a rate of 60Hz under a 4X objective. The minimum acceptable values 
were set at 20% motility, minimum contrast at 35, minimum cell size at 4 pixels, 
progressive cells had to have a path velocity (VAP) of 50.0μ/s, a straightness of 50%, and 
of the slow cells, a VAP of 10.0μ/s, and a straight line velocity (VSL) of 0.0μ/s. Five 
fields were captured in each treatment and the results run through the CASAnova 
analysis software developed by Goodson et al. (2011). The data capture files (.DBT) were 




1.2.4 Aim 2 Methods 
1.2.4.1 Protein Extraction 
Mice were sacrificed by CO2 followed by cervical dislocation, and the cauda 
epididymides removed and cut to allow mouse sperm cells to swim out in NC media for 
ten minutes at 37°C. Following swim out, the remaining epididymis tissue debris was 
removed from the 2ml-eppendorf (Radnor, PA), and sperm cell suspension split amongst 
1.5ml-eppendorf tubes for further treatments if necessary. Cells were then centrifuged for 
two minutes at 12500rpm; the supernatant was discarded, leaving the pellet. To wash the 
cells and prevent further protein degradation, cold 1X filter sterilized PBS was added to 
the pellet. The cells were then centrifuged at 13,400rpm for three minutes to re-pellet 
them. The supernatant was discarded and the tubes placed on ice immediately. For cell 
lysis, 5X sample buffer was added to the cell pellets. The tubes containing the cell lysates 
were boiled for four minutes and centrifuged again for five minutes at 13,400rpm. The 
supernatant contained the protein and was transferred to a new tube and saved at -80°C 
for future use. For analysis of signaling events by Western Blotting of PY or PKAS, 
sperm cell lysates stored at -80°C were used within 24-48h after sample collection. 
1.2.4.2 Sperm Capacitation 
Following swim out in NC media, sperm was allocated into individual treatment 
tubes and exposed to the previously described Cap media for one hour at 37°C. 
Typically, the treatments were as follows: NC, Cap, Cap + DMSO (at 1%), Cap + CC @ 
0.1μM, 1μM, 10μM, 30μM, 50μM, and 100μM. For appropriate exposure to this 
inhibitor, cells were pre-incubated in the NC media with the inhibitor for 15 minutes 
prior to the introduction of the Cap media. 
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1.2.4.3 Compound C 
When testing for the effect of CC on sperm, cells were pre-incubated in NC media 
and varying concentrations of CC for 15 minutes prior to the addition of Cap media. 
Following the addition of Cap media, cells were incubated for an hour to induce sperm 
capacitation. Samples were then either preserved via protein extraction, or used for 
further experimentation. 
1.2.4.4 Western Blot 
The protein extracts were thawed, 2-mercaptoethanol (5% βME, from Bio-Rad) 
was added to each extract (at 5% of total volume), and boiled at 100°C for three minutes. 
Samples were then centrifuged for a short spin at maximum speed and loaded into a 
polyacrylamide gel. The gel percentage varied depending upon the type of initial primary 
antibody to be applied: AMPK required a 10% gel, and PKA required an 8% gel.  
An electrophoresis was performed and the proteins were transferred to 0.45μm PVDF 
membrane for 90 minutes (Laemmli 1970).  
1.2.4.4.1 Anti-PKA substrates 
The membrane was blocked with 5% milk (prepared in 1X T-TBS –TBS 
containing 0.1% Tween-20) for an hour at ambient temperature, then incubated with anti-
PKA substrate (rabbit monoclonal, Cell Signaling) at 1:10,000 prepared in 5% BSA/T-
TBS 1X overnight at 4°C. The following day, the membrane was washed with 1X T-TBS 
and then incubated with anti-rabbit-HRP (GE Healthcare) at 1:10,000 in 5% milk/T-TBS 
1X for two hours at room temperature. Again, the membrane was washed and finally the 




Following exposure to PKAs, membranes were stripped and re-probed with 
another antibody. Stripping solution comprised of 62.5mM Tris-Cl (pH 6.5) and 2% SDS 
was combined with βME (0.74% of total volume) and poured on the membrane. The 
membrane was incubated at approximately 59°C for 15-30 minutes on a rocker. After 
discarding the solution, the blot was rinsed with MilliQ water ten times and then washed 
for longer increments with 1X T-TBS to rid the membrane of βME.  
To probe with a different primary antibody, the membrane was blocked again; 
when using anti-phosphotyrosine (αPY), the membrane was blocked with 20% fish skin 
gelatin (Sigma-Aldrich) for one hour at room temperature, incubated with αPY at 
1:10,000 in T-PBS 1X (PBS plus 0.1% Tween-20) overnight at 4°C, then washed with T-
PBS 1X, incubated with anti-mouse-HRP at 1:10,000 prepared in T-PBS 1X for one hour 
at room temperature, washed with 1X T-PBS, and lastly, developed using ECL.  
1.2.4.4.3 Tubulin  
To blot for tubulin antibody, following stripping, the membrane was blocked with 
5% milk in 1X T-TBS for one hour at ambient temperature. The primary antibody was 
monoclonal E7 at either 1:1000 or 1:5000 in 1% milk in T-TBS 1X overnight at 4°C, the 
membrane was washed the next day, then incubated for one hour at room temperature 
with anti-mouse-HRP at 1:10,000 in 1% milk in T-TBS 1X. The membrane was washed 
for an hour and then developed with ECL. 
1.2.4.4.4 AMPKα  
When probing for AMPK, either a monoclonal (clone F6) or polyclonal anti-
AMPKα antibody was used. Typically 2 x 106 mouse sperm cells were loaded per lane. 
 13 
Following protein transfer onto a PDVF membrane, the blot was blocked with 5% non-fat 
milk in T-TBS for one hour at room temperature. The primary antibody was suspended in 
a 1% milk solution at a concentration of 1:1000. The subsequent day, the membrane was 
washed with T-TBS. The secondary antibody was applied –the monoclonal primary 
antibody required anti-mouse secondary antibody, while the polyclonal primary antibody 
necessitated anti-rabbit –at 1:10,000 in 1% milk and T-TBS. The membrane was washed 
for a few short washes in T-TBS and the membrane was developed using ECL. 
1.2.4.5 Immunoprecipitation 
Sperm samples for immunoprecipitation were prepared in NC media and the 
entire swim out of sperm cells from one mouse was pelleted and the supernatant 
discarded. Performed on ice, RIPA+ the inhibitors NaVO4 (1mM), βGP (40mM), and 
50X protease inhibitor was prepared and added directly to the pellet of cells. For cell 
lysis, the tube with the cells was incubated for 15 minutes on ice and vortexed every five 
minutes; it was then centrifuged for five minutes at 4°C at 3000rpm. 
The supernatant was separated from the pellet. Add 10% SDS to the RIPA+ 
solution at a concentration of 0.5%. This new solution was added to the remaining pellet, 
to proceed with a sequential protein extraction for sperm cells. Incubation on ice and 
vortexing every five minutes was repeated for a total of 15 minutes. It was centrifuged 
again for five minutes at 4°C at 3000rpm and the supernatant was pooled with the 
previous supernatant. A pre-determined volume (based on the number of cells desired per 
well) was removed and put into a separate tube (this was an “input” sample; the other 
portion was used for immunoprecipitation). To the IP samples, PBS+ inhibitors were 
added to ensure not more than 0.1% of SDS in final IP reaction; anti-AMPK-alpha was 
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added at 1:100 (or tubulin (monoclonal E7) at 1:500 in control IP). These tubes were 
incubated on a rotator at 4°C for 1.5 hours.  
During incubation, an equal combination of A-beads and G-beads were prepared 
via washing with cold PBS + 0.1% Tween-20 (Sigma-Aldrich) and then the supernatant 
removed and the tubes put on ice. After incubation on the rotator, the tubes were spun 
down and the supernatant, containing the AMPK-Ab complexes, transferred to the tubes 
containing the beads, and the reaction was mixed. The tubes were put back into the cold 
rotator for an additional two hours.  
Using a magnetic rack, the beads were washed three times and the supernatant 
discarded. New tubes were prepared with βME while 2X sample buffer was added to the 
beads and vortexed. Tubes were then boiled for ten minutes, vortexed, and spun down at 
13,400rpm for one minute. The supernatant was removed and put into the tubes 
containing βME, leaving the beads behind. These samples were stored at -20°C until their 
use the next day. 
1.2.4.6 CASA 
After the hour of capacitation (as described above), 20μl of sample (equivalent to 
approximately 2-4 x 105 cells) were removed from the middle of each tube and put into a 
single slide’s chamber. CASA/CASAnova then analyzed samples.  
1.2.4.7 Acrosome Reaction 
After an hour of incubation in capacitating medium, the calcium-ionophore 
(A23187) (Sigma-Aldrich) was added at a concentration of 10μM/reaction. Samples were 
incubated for another 30 minutes at 37°C. Parallel samples without A23187 were 
processed for assessment of spontaneous AR. In addition, samples were collected after a 
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very brief incubation of sperm samples in Cap medium (considered time zero, T0) and 
taken as AR controls. 
1.2.4.8 PNA Fluorescence Imaging 
Following the induction of the acrosome reaction, one milliliter of 4% 
paraformaldehyde (PF) (Fisher, Framingham, MA) was added to each treatment and 
samples incubated for ten minutes at room temperature to fix the cells in solution. To 
remove the PF, tubes containing the samples were centrifuged at 2,500rpm for five 
minutes, the supernatant discarded, a milliliter of 1X PBS added, centrifuged again at 
2,500rpm for five minutes, the supernatant discarded, and the pellet resuspended in 200μl 
1X PBS.  
Using a wide-bore pipet tip (VWR), a 25μl droplet of each sample was put onto 
clean slides (Gold Seal Rite-On Micro Slides, Portsmouth, NH) and allowed to air-dry for 
5-10 minutes. To permeabilize the cells, 20μl of 100% Methanol (Fisher) was added to 
each droplet for 30 seconds then aspirated. To ensure the remaining methanol was 
removed, the slides were washed with 20μl of 1X PBS for one minute each, then the PBS 
was aspirated; this was performed three times. To detect the cell’s acrosomal region, 20μl 
of FITC-PNA (prepared at 1:50 from stock, from Molecular Probes Eugene, OR) was 
applied to each treatment; the slides were then incubated for 30 minutes in a dark 
chamber. 
Again, the cells were exposed to a series of washes and aspirations with 1X PBS. 
A mounting media comprised of glycerol:PBS (9:1) (glycerol from Fisher) was applied to 
each treatment (4μl) and a clean coverslip (Corning, No. 1.5 from Tewksbury, MA) was 
applied to each slide. Using a fine pair of forceps, the coverslip was lightly pressed into 
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the slide to ensure even coverage of the mounting media throughout the treatment. The 
slides were then sealed with nail polish and stored at 4°C in a dark chamber. Cell 
counting and AR assessment was performed within 24h. 
Slides were read and visually quantified via differential interface contrast (DIC) 
and fluorescent microscopy using a Nikon Eclipse TE300 and a 60X objective. The 
camera was an Andor/Zyla and the software used was NIS Elements. 
1.2.4.9 Viability 
To monitor the viability of sperm cells, especially following the addition of CC, 
the Life Technologies Live/Dead® Sperm Viability kit was utilized. Reagents were 
prepared as indicated in the protocol. Following capacitation, a small volume from each 
treated sample was put into a separate tube (approximately 1-2 x 106 sperm cells were 
removed per sample for viability testing). The prepared SYBR 14 (in kit) was added to 
the new tube at 100nM and incubated for five minutes at 37°C; the propidium iodine (PI) 
was added at 12μM and incubated at 37°C for an additional five minutes. To wash away 
the excess PI, the tubes were centrifuged for five minutes at 2,500rpm and the 
supernatant discarded; 500μl of HEPES buffer was added to each tube. The samples were 
centrifuged again at the same speed, and for the same duration, and the supernatant was 
discarded. Pellets were resuspended in approximately 200μl of HEPES buffer and were 
mounted to slides and visually quantified using the same technique described in the 
fluorescent imaging section (paragraph 1.2.3.2.8). By staining with two unique reagents, 
the viability status of each cell was determined. SYBR 14 is a small, membrane-
permeable molecule that can enter sperm cell nuclei and produce a green signal under 
fluorescent imaging. PI is excluded from viable cells and is a known membrane-
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impermeant dye; however, when a cell dies or its structure is seriously damaged, their 
nuclear pores expand, allowing for PI to enter. A red signal is emitted under fluorescent 
microscopy (Garner and Johnson 1995).    
1.2.4.10 In Vitro Fertilization (IVF) 
In vitro fertilization was performed over 4-5 days beginning by injecting the 
female mice intra-abdominally with 5IU with pregnant mare’s serum gonadotropin 
(PMSG from Sigma) (Day 1) to induce superovulation. Thirteen hours prior to sacrifice 
(evening of Day 3), females were injected intra-abdominally with human chorionic 
gonadotropin (hCG, from Sigma); IVF media was also prepared on Day 3. Capacitating 
TYH media was prepared and 500μl of media was put into well plates (Thermo Scientific 
nunclon surface). The well plate and remaining Cap media were placed in a 37°C CO2 
incubator (5.1% CO2) with a loose lid for appropriate O2/CO2 exchange. 
The following morning (Day 4), a single male mouse was sacrificed and the 
sperm was allowed to swim out in NC media for ten minutes. The sperm was pre-
incubated with the CC (30μM or 100μM) or H89 (50μM) inhibitors followed 
centrifugation at 2,500rpm for five minutes. The supernatant was discarded and the pellet 
was resuspended in Cap media. The remaining inhibitor was added to bring it up to the 
appropriate concentration and the whole sample was transferred to a 2-ml tube. 
Capacitation was allowed to occur over the next hour and a half in the CO2 incubator. 
While the sperm was undergoing capacitation, the female mice were sacrificed. 
The reproductive tracts of the females were removed and put into warmed M2 media. 
Using a fine pair of forceps, the oviducts were punctured to release the cumulus/oocyte 
complex. The complex was carefully transferred to a separate, fresh dish of M2 media 
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using a glass mouth pipet in order to separate the complex from the reproductive tract. 
The oocytes were then transferred to the IVF well plates.  
When the sperm was capacitated, 10μl of sperm was added to the well plates 
containing the oocytes. Inhibitors were added to the wells (if necessary) and the entire 
plate was incubated for four hours in the CO2 incubator. After that time period, oocytes 
were washed and returned to the incubator for approximately 20 hours. The next day 
(Day 5), oocytes were observed under the Nikon microscope at 20X and 60X 
magnification. Oocytes were quantified as 2-cell, 1-cell, or degraded embryos. IVF was 
also double-checked on Day 5. 
1.2.4.11 Statistical Analysis 
 For all quantified data in Chapter 3, Analysis of Variance (ANOVA) was used for 
statistical analysis. In most cases, the data (percentages) were transformed to comply with 
the assumptions necessary for ANOVA analysis. Post-test comparisons were made using 























IN VITRO SCREENING FOR SMALL-MOLECULE KINASE INHIBITORS OF TESTIS-SPECIFIC 
SERINE KINASE 1 (TSSK1) 
2.1 Rationale 
 TSSKs are a unique family of serine/threonine kinases localized to the testes; the 
conserved expression of TSSK genes and well-established role of phosphorylation of 
sperm proteins suggests that TSSKs have a role in sperm function (Hao, Jha et al. 2004, 
Li, Sosnik et al. 2011). TSSK1 was the first described member of the TSSK family 
(Bielke, Blaschke et al. 1994) and it was found in both an active and inactive state. 
Members of the TSSK family are typically considered “active” when they are 
phosphorylated; phosphorylation of the hydroxyl group of either the threonine or serine 
residue within the T-loop using ATP as the phosphate donor activates the kinase. 
According to ex vivo work performed by Bucko-Justyna, there is evidence of TSSK 
autophosphorylation (Bucko-Justyna, Lipinski et al. 2005, Xu, Hao et al. 2008), which 
would suggest that the kinase has the ability to self-activate. The goal of our lab is to find 
a small-molecule inhibitor that is specific to TSSK1. Since our group found TSSK1 to be 
the most soluble when analyzed in mouse and human sperm samples (Li et al., 2011), and 
it would prove more amenable to biochemical characterization in vivo and in vitro, 
TSSK1 was chosen as the model target for the search of a kinase inhibitor.  
 In order to progress to high throughput screening (HTS), there are a number of 
steps necessary to perform prior. Based on the steps outlined by Brooks (Brooks 2012) 
among others, it is necessary to define reagents and instruments, validate the assay, and 
optimize conditions before engaging in HTS. The following experiments were designed 
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to (a) determine assay feasibility, (b) establish experimental parameters, and (c) begin to 
look at a reduced battery of kinase of potential inhibitors as a method to assess the (d) 
sensitivity of a homogeneous TSSK1 activity assay in a small scale system, which could 
then by adapted to an HTS of a larger library of compounds. 
2.2 Results  
2.2.1 Testing Assay Sensitivity 
 As shown in Figure 9, the feasibility of using the ADP-Glo™ kit was tested using 
recombinant purified TSSK1 (rTSSK1). Using the substrate myelin basic protein peptide 
(MBPp) and ATP, rTSSK1 kinase reactions were performed in a 96-well plate assay to 
determine whether the ADP-GLO detection system was effective for quantifying TSSK1 
kinase activity in vitro. Prior to running the assay, the possibility of TSSK1 
autophosphorylation was acknowledged (Bucko-Justyna, Lipinski et al. 2005, Xu, Hao et 
al. 2008); to investigate the rate of autophosphorylation, rTSSK1 was put through the 
ADP-Glo™ assay without a substrate, alongside treatments that included substrate –in 
this case, MBPp. While there was a noticeable amount of autophosphorylation in the 
rTSSK1 at 25ng and 50ng, what was more significant was that when utilizing as low as 
25ng of rTSSK1 in a 96-well plate reaction, rTSSK1 activity could be detected in 
comparison to reactions containing ATP alone (control). In addition, there was a dose-
dependent response to the amount of kinase used; the kinase activity at 50ng of rTSSK1 
was nearly double that of 25ng. Of equal importance was that the experiment 
demonstrated that the assay was functional using this kinase, and kinase activity was 
detectable at the lower concentration. As a result of this series of experiments, it was 
determined that rTSSK1 at 25ng could be used for future assays.  
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 2.2.2 Testing Substrate Sensitivity 
To continue establishing assay parameters, it was necessary to identify the most 
appropriate substrate. Our lab had demonstrated that MBPp was a suitable substrate for 
TSSKs, due to positive published data from radioactive assays utilizing TSSK1 and 
TSSK2, and also based on studies by others (Bucko-Justyna, Lipinski et al. 2005). 
However, more recent literature indicated that the peptide, AMARA, could also be a 
suitable substrate for use with TSSKs (Jaleel, McBride et al. 2005), SIK, and AMPK 
kinases (TSSKs are members of the AMPK branch of the kinome). To determine which 
of the two substrates, MBPp or AMARA, was more sensitive to phosphorylation by 
TSSK, an assay was designed to compare the two substrates (Fig. 10). Both substrates 
were tested at various concentrations from 0-100μM to compare the relative 
luminescence units (RLU) output. From the resulting graph, significant differences 
between the RLU outputs of the two substrates can be seen. This experiment indicated 
that AMARA was more sensitive and likely more specific to rTSSK1, showing a nearly 
10-fold increase of RLU output versus MBPp. Further assays were performed using 
AMARA as the substrate. 
2.2.3 rTSSK1 Concentration Curve 
Following the previous determinations and because ultimately, the overall 
endpoint was to bring this assay to HTS, investigation into the suitability and 
functionality of the assay at lower concentrations was the next step. To do so, ATP and 
AMARA were both added at 100μM to a 384-well plate and rTSSK1 was scaled-down to 
concentrations ranging from 0-18.25ng per reaction, specifically chosen to lower amounts 
than previous assays in order to test sensitivity. As shown in Figure 11, we were able 
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detect changes in TSSK1 kinase activity at concentrations as low as 2.5ng in a 384-well 
plate format. Until this point, all assays were performed in a 96-well plate with a total 
reaction volume of 100μl; with this new information, we were able to reduce the total 
reaction volume by using smaller reagent volumes. Subsequent assays were performed in 
a 384-well plate with a total reaction volume of 25μl. The possibility of quantity 
reduction was necessary for HTS, and this particular experiment encouraged continuation 
of work with this particular assay on this specific kinase. 
2.2.4 Testing rTSSK1 Inhibition In Vitro 
As stated previously, the goal of this series of experiments was to look for 
inhibitors of TSSK1. Using the assay parameters established above, an assay was 
performed that incorporated a battery of known kinase inhibitors, including sperm-
specific targets such as PKA or Src. Some inhibitors were broad spectrum, such as 
Staurosporine that inhibits several protein kinases, whereas others were more specific, 
inhibiting PKA or AMPK. Listed in the table in Figure 12 are the inhibitors used, listed in 
order of increasing selectivity: from the most broad-spectrum to the more specific 
inhibiting reagents. To each reaction, a different inhibitor at 100μM or DMSO (control) 
was added alongside rTSSK1 and AMARA. The corresponding RLU output was graphed 
in Fig. 12; based on the graph it can be seen that CC and SKI 606 were the most effective 
compounds to inhibit rTSSK1. Further investigation of CC was performed – because it is 
an AMPK inhibitor, and TSSKs are found on the AMPK branch, it was hypothesized that 
CC might be a suitable inhibitor of TSSKs.  
Figure 13 depicts the inhibitory effect of CC on rTSSK1 at concentrations from 
0.1μM-100μM. The downward curve indicated a dose-dependent effect of CC on 
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rTSSK1. Beginning at ~25-30μM, there was a significant drop in RLUs, suggesting a 
more significant inhibitory effect on rTSSK1 activity.  
In summary, the abovementioned series of experiments provided a strong 
rationale and some tools for further experimentation with CC by evaluating sperm 


















IN VIVO TESTING OF SMALL-MOLECULE KINASE INHIBITORS OF AMPK/TSSK 
3.1 Rationale  
Following investigation of Compound C (CC) and its inhibitory effect on rTSSK1 
activity in vitro, the next step was to look at CC in an in vivo model system. Based on the 
proven relevance of these endpoints in evaluating sperm function in mice and other 
species, we decided to look at the effect of CC on (a) sperm signaling events via 
phosphorylation; (b) sperm motility; (c) the occurrence of acrosome reaction, and (d) its 
effect on fertilization ability in vitro.  
 Thus far, there is no clear evidence regarding the role of AMPK in mouse sperm. 
Due to this information, the findings from Aim 1 of this Thesis (specifically Figures 11 
and 12), and the fact that Compound C is a known AMPK inhibitor, we considered it 
very relevant to (a) determine whether AMPK is in fact present in mouse sperm; and (b) 
study the effect of a known inhibitor of the AMPK superfamily on mouse sperm function. 
Among the possible outcomes expected from studies presented in Aim 2 is that AMPK is 
absent in mouse sperm and thus mouse TSSK1might be the main kinase target of 
inhibition by CC.  
The importance of studying the effects of CC on PKA and PY are due to the role 
the two events play in capacitation, and motility. Referring to Figure 3, phosphorylation 
of PKA substrates is an indication of capacitation (Aitken, Paterson et al. 1995, de 
Lamirande, Leclerc et al. 1997, Leclerc, de Lamirande et al. 1997, Visconti, Johnson et 
al. 1997, Breitbart and Naor 1999). We were interested in the effects of CC on 
capacitation; towards this goal, we investigated PKA substrate phosphorylation when 
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samples were exposed to CC. While it is not well understood what events occur between 
PKA substrate phosphorylation and tyrosine phosphorylation (PY), it is known that PY is 
downstream of PKA in the cellular pathway. In an attempt to orient TSSKs within the 
pathway, we looked at the effects of CC on both PKA substrates and PY. 
As described previously, prior to fertilization the sperm must undergo the 
acrosome reaction (Dan 1952, Barros, Bedford et al. 1967). It was crucial to investigate 
the effects of CC on the acrosome reaction, as the AR is critical to successful 
fertilization. Most of our analysis focused on the effect of CC on sperm spontaneous AR; 
in some cases, CC effect was also assessed after AR was induced using a calcium 
ionophore per Wertheimer (and references therein) (Wertheimer, Krapf et al. 2013). A 
visualization of the methodology used for these experiments can be found in Figure 6. It 
is worth noting that the Live/Dead® Sperm Viability Kit was consistently run in parallel 
to ensure that CC was only affecting AR or motility, not viability (data not shown). 
 In order for a sperm to reach and then fertilize an egg, it must be not only motile, 
but must have reached a hyperactivated state. First suggested by Yanagimachi, sperm 
experience a change in motility before fertilization of the oocyte, termed hyperactivation 
(Yanagimachi 1981, Suarez, Katz et al. 1983, de Lamirande, Leclerc et al. 1997). 
Hyperactivation is characterized by an increase in rapid movement creating a frantic, 
increased amplitude and beat frequency of flagellar waves creating a whiplash motion, 
and increased lateral head displacement (Mortimer and Mortimer 1990, de Lamirande, 
Leclerc et al. 1997). Utilizing these parameters, we applied a computerized system to 
measure, quantify, and categorize sperm; this system is known as Computer-Assisted 
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Sperm Analysis (CASA). We took advantage of this system to determine the effects of 
CC on sperm motility and hyperactivity. 
 The ultimate test of CC’s efficacy on sperm’s ability to fertilize was to perform an 
in vitro fertilization (IVF) experiment. Experiments were designed to allow observation 
of the effect of CC on sperm (a), on oocytes (b), and on sperm and oocytes together (c). 
3.2 Results – Aim 2.1 
3.2.1 Investigation of AMPK in Murine Sperm 
To investigate the presence of AMPK in mouse sperm, an initial test by Western 
blotting was performed on pelleted CD1 mouse cells. Protein was extracted under 
varying conditions of detergent stringency: Triton, RIPA, and SDS. The increasing 
stringency of extraction was to ensure all parts of the sperm were broken down and the 
protein extracted. Approximately 2 x 106 cells were loaded per lane. Western analyses 
blot were run using a polyclonal AMPK antibody at a concentration of 1:1000. AMPK 
predicted molecular weight (MW) in somatic cells is ~62kDa. HEK293T cells (human 
embryonic kidney cells, a cell line known to contain AMPK) were included to validate 
the antibody, and a total cell extract from murine C2C12 cell (myoblasts) was also used 
to validate this antibody to recognize AMPK in mouse cells. According to this initial test, 
AMPK was not detected in mouse sperm (data not shown). In order to confirm these 
results, two distinct western blots were performed next; three individual mice were 
sacrificed and their sperm extracted under SDS conditions. Roughly 2 x 106 mouse sperm 
cells were loaded per lane in each gel; in parallel, 7.5 x 104 293T cells were loaded as 
positive control. One blot was probed using a monoclonal AMPK-α antibody (clone E6, 
Fig. 14a) also at a concentration of 1:1000 while the other was probed with the polyclonal 
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AMPK-α at the same concentration (blot not shown). As the Western blot in Figure 14(a) 
indicates, the monoclonal antibody recognized AMPK in both positive controls, human 
and mouse cells, at the expected MW of 62kDa. However, and despite a long exposure 
prior to film developing, AMPK was nearly undetectable in mouse sperm samples even 
when a monoclonal antibody is utilized. 
In order to further assess these findings, AMPK immunoprecipitations were 
performed, followed by Western blotting using C2C12 lysate as a positive control, and 
293T cells as a secondary biological control; in some cases, IP reactions for AMPK from 
293T were carried out in parallel. Each IP sample had an accompanying input sample. 
For 293T cells, a RIPA-soluble extract was prepared and about 7.5 x 104 cells were 
loaded per lane; the IP sample contained ~4 x 106 cells. To each lane, approximately 1.5 
x 106 of mouse sperm cells were loaded as murine RIPA-extracted input samples while 
~2.5 x 107 mouse sperm cells were loaded as IP samples.. Although this experiment was 
run multiple times using both a monoclonal and a polyclonal antibody (both at 1:100), as 
well as with secondary antibodies against either immunoglobulin light chain (L) only or 
high and light (H+L) chains together, AMPK was not detectable in mouse sperm under 
the several experimental conditions tested. Figures 14 (c & d) are representative of what 
was found most often throughout multiple experiments. The Western blot performed 
using monoclonal antibody suggested that there may be barely-detectable amounts of 
AMPK in mouse sperm, but IP blots suggest that AMPK may not be in mouse sperm, at 
least not consistently in all mouse sperm samples analyzed. In very few cases, it could 
only be detected when sperm was highly concentrated and/or at high exposure times prior 
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to developing, implying that there may only be small amounts, if any, of AMPK present 
in mouse sperm.  
3.3 Results – Aim 2.2 
3.3.1 Effect of Compound C on Sperm Signaling Events  
Regardless of whether or not AMPK was present in mouse sperm, it was 
necessary to discern if CC effected sperm signaling. Utilizing the pathway in Figure 3 as 
a model, it was essential to investigate the two primary areas of the pathway that could be 
affected: PKA-dependent phosphorylation and tyrosine phosphorylation (PY) events. It 
has been well established that phosphorylation of PKA substrates is indicative of the 
activation of this known pathway following upstream events (bicarbonate-dependent 
activation of soluble adenylate cyclase, cAMP, and then PKA) (Visconti, Moore et al. 
1995, Muratori, Luconi et al. 2009, Visconti 2009). Downstream of PKA is tyrosine 
phosphorylation. PY signaling is indicative of whether or not sperm have achieved a 
capacitated state (Visconti, Bailey et al. 1995). The two signaling events act as a point of 
reference within the sperm signaling pathways, thus allowing for a rational evaluation of 
TSSK1 in the signaling events conducive to sperm capacitation and fertilizing ability. In 
this Aim, the effect of Compound C on these signaling cascades was analyzed.  
Looking at signaling trends, rather than for a specific band, from the PKA 
substrate blot (Fig. 15a) it can be seen that there was no significant change in PKA signal 
strength even as the concentration of CC increased from 1μM to 100μM. The lower blot 
(Fig. 15b), PY, showed a different trend than the PKA blot; as concentrations of CC 
increased, PY signaling decreased, indicating a dose-dependent inhibitory response. 
While there are clear differences between the controls –Cap shows a darker signal 
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(indicative of successful capacitation) than non-cap (where almost no signal is detected), 
the DMSO-treated sample appears to produce similar signaling as the Cap, but starting 
around 10μM, a significant decrease in signaling can be observed. Based on these results, 
the signaling trend suggested that CC was acting on a target(s) probably downstream of 
PKA but upstream of PY. Figure 15c is the phosphorylated hexokinase. In murine sperm 
PY blots, the phosphorylated hexokinase may be used as an internal loading control as it 
is constitutively phosphorylated on tyrosine (Asquith, Baleato et al. 2004).  
3.3.2 Computer-Assisted Sperm Analysis 
Using the CASA system described in Figure 16, total motility and hyperactivity 
of sperm (average) was evaluated when sperm were exposed to CC at varying 
concentrations. Both Cap and Cap + DMSO (at 1%) were used controls, providing a 
baseline with which to compare the CC-treated cells. As per the parameters outlined by 
Goodson et al. (2011) based on the kinematics described by WHO (2010), sperm 
underwent capacitation and were subjected to CC treatments; 20μl of sample containing 
approximately 2-4 x 105 mouse sperm cells were then removed from the experimental 
tubes and introduced to the 2-chambered slides for data capturing and analysis. From the 
CASAnova analysis, the total number of motile sperm was calculated for each treatment. 
The average of sperm motility and hyperactivation acquired from several experiments 
(N>4) was calculated, and Figure 16 shows the resulting bar graph. The results were 
analyzed using ANOVA to calculate significant variance; post transformation, data 
underwent the Tukey test. The resulting motility of sperm exposed to CC at either 50μM 
or 100μM was significantly less than that of the controls (compared against the Cap 
control). From those motile cells, the average number of hyperactive cells was calculated 
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using the CASAnova software. The lower graph of Figure 16 displays these results; again 
the numbers were analyzed using ANOVA and post-test Turkey test. From the graph, it 
can be seen that there was a significant decrease in hyperactive sperm when exposed to 
30μM or higher concentrations of Compound C. 
One area that had yet to be explored was whether the effect of CC on sperm 
motility was reversible. According to numerous sources, the inhibitor should be 
reversible (Hurtado de Llera, Martin-Hidalgo et al. 2012, Liu, Chhipa et al. 2014); 
however, under the couple of experimental conditions we tried in the current study (data 
not shown), it was not feasible to reverse the effects of the inhibitor. Replicates of the 
following experiments were tried: following capacitation with exposure to CC, a 10% of 
the sample was removed and put into fresh Cap media without CC and then incubated for 
another hour. After the hour of incubation, 20μl was inspected using CASA. Two 
challenges arose due to this experimental design: there were not enough sperm cells to 
analyze, and none of the sperm was moving, even at low concentrations of the inhibitor, 
indicating that serial dilution was an ineffective method of reducing the concentration of 
CC in the media. The second method attempted included a centrifugation and wash using 
Cap media following incubation with CC and capacitation. This wash method was more 
successful than that of serial dilution, but even after allowing the sperm to incubate in the 
clean media for four hours beyond capacitation (with CASA analysis or video 
microscopy at 20x magnification every 30-60 minutes) there was no significant 
movement or indication of recovered motility. However, in the videos taken some sperm 
cells displayed a “shivering” motion. Due to this “shiver,” I wondered whether or not the 
 44 
sperm undergo a type of paralysis, however there is no evidence in the sperm/CC 
literature that would support this thought. 
3.3.3 Compound C and the Acrosome Reaction 
Next, in Figure 17 we looked at the effects of CC on the AR. The controls included Cap 
samples, and Cap + DMSO (at 1%), both with and without ionophore; this ensured that 
the ionophore was functioning properly while acting as an experimental control for 
comparison, and to control for the ionophore effect. Using fluorescent FITC-PNA 
staining (as per the protocol in Fig. 6) and DIC/green channel (‘GFP filter’) microscopy, 
the number of acrosome-reacted versus unreacted cells was quantified as per Yoshida 
(Yoshida, Ito et al. 2010). Looking at the upper panel in Fig. 16, the control Cap cells 
(without ionophore) displays numerous intact acrosomes –the green slivers indicated by 
PNA staining under the GFP filter are the intact acrosomes of individual mouse sperm 
cells. The merged overlay and the region of interest (ROI) give clear images of fully 
intact acrosomes and initial stages of the AR. From this panel, it can also be seen that 
very few (approximately two cells in this image) have already undergone the AR 
(indicated by the lack of GFP in the acrosome). This was considered “spontaneous 
acrosome-reacted” sperm. Upon treatment with CC, there is a significant decrease in 
PNA staining; the merged overlay and ROI are a visual representation of acrosome-
reacted spermatozoa. Although it was anticipated that CC could inhibit the AR as 
concentrations increased, the opposite effect occurred as is evident in Fig. 16 (bar graph). 
Instead of inhibiting the AR, CC seems to have had the same or a similar effect as would 
a calcium ionophore, suggesting that the inhibitor is actually acting upon a kinase 
involved in induction of mouse sperm AR. The data shown is of treatments in Cap 
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conditions but without an ionophore (except in the indicated treatment, bar on far right). 
The bar graph also provides a few other important pieces of data: T=0 is the spontaneous 
AR; ~55% of sperm undergo spontaneous AR in average among several experiments 
performed (which is also consistent with published observation by other authors). 
Interestingly, CC at concentrations ≥10μM display similar rates of AR in comparison to 
the Cap with ionophore treated sample. ANOVA statistical analysis was performed and a 
post-test Fisher analysis was performed to compare the data against the T=0 result. From 
this analysis, all treatments with CC and the ionophore are statistically significant 
compared to T=0. Viability was run in parallel (data not shown) using the Live/Dead® 
Sperm Viability kit to ensure CC was not affecting sperm viability. 
3.3.4 In Vitro Fertilization 
Finally, to test the effect of CC on the sperm’s ability to fertilize, in vitro 
fertilization (IVF) was performed. Using a slightly different experimental design than in 
previous experiments, a range of treatments was performed to test a few different 
possible scenarios. Firstly, a 1x TYH capacitating medium containing BSA (4mg/ml) and 
HCO3- (15mM) was prepared. This capacitating media was prepared 13 hours prior to use 
and was kept in a CO2 incubator at 37°C to allow appropriate CO2 exchange. The day of 
the experiment, mTYH NC media was prepared. Experimental treatments were as 
follows: Capacitating media plus DMSO (at 1%), sperm pre-incubated in TYH Cap 
media with 30μM CC or 100μM of CC, oocytes pre-incubated with 100μM CC, sperm 
pre-incubated with H89 at 50μM, and sperm not only pre-incubated with 100μM of CC, 
but also co-incubated – meaning that CC was added to the dish containing both the sperm 
and oocytes for a final concentration of 100μM CC maintained throughout the entire 
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experiment. Of equal importance to this experiment was that with sperm cells (or 
oocytes) considered “pre-incubated,” they underwent a wash using their respective 
medium prior to incubation with oocytes (or sperm) in order to minimize carry-over of 
CC persisting in the experimental environment. After initiation of the sperm-oocytes co-
incubation, the dishes were kept in the CO2 incubator at 37°C; four hours later, the 
oocyte/cumulus complex was washed and further incubated for an additional 16-20 
hours. The next day, the oocytes were examined at 60X magnification and the number of 
1-cell and 2-cell oocytes was counted. Figure 18 shows images representative of the 
majority of fertilization stages (or the lack thereof) seen following incubation. The 
DMSO-treated sperm (control) typically incurred high rates of fertilization, as depicted 
by embryos in the 2-cell stage (Fig. 18a). Oocytes incubated with sperm exposed to CC at 
30μM showed 2-celled embryos (18b), but only 1-celled oocytes at 100μM (18c). It was 
interesting that in Figure 18(d) the concentration of cumulus cells surrounding the oocyte 
was very high. According to the literature, cumulus cells contain AMPK (Santiquet, 
Sasseville et al. 2014); CC inhibited the cumulus expansion normally experienced by 
cumulus cells prior to fertilization. Without cumulus expansion, the sperm are unable to 
reach the oocyte. Figure 18e demonstrates that even though the oocytes were exposed to 
CC, the washing step in the protocol decreases the concentration of CC enough to allow 
for cumulus expansion and occasional fertilization. The negative control, sperm pre-
incubated with H89, a known PKA inhibitor, showed a low number of fertilized cells, as 
expected (18f). 
 As described, the number of 1-cell and 2-cell oocytes was quantified. Oocytes in 
the 1-cell stage were considered unfertilized and those in the 2-cell stage were 
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categorized as fertilized. In some instances oocytes were considered “degraded” and were 
put into the “unfertilized” category as they were unable to be fertilized due to oocyte 
deformation. The averages of three experiments are expressed in the accompanying graph 
in Figure 18. The graph indicates successful fertilization of oocytes with DMSO-treated 
sperm cells (positive control), and a significantly low amount of fertilized oocytes in 
sperm cells incubated in H89 (negative control). At the lower concentration of CC, some 
oocytes were fertilized; at higher concentrations and when co-incubated with CC, almost 
no oocytes were fertilized. When oocytes were pre-incubated with CC, there was some 
fertilization, significantly higher than when the sperm was pre-incubated, but less than 
the control and when sperm was pre-incubated at 30μM. It is likely that when the oocytes 
were washed following pre-incubation, the concentration of CC remaining with the 
cumulus cells and oocytes was diminished to a level that would allow sperm to fertilize 
the oocytes. To determine statistical significance of fertilization rates, the data was tested 
















CONCLUSIONS, DISCUSSION, & FUTURE DIRECTIONS 
4.1 Conclusions & Discussion 
 The major finding of the in vitro studies performed for this Thesis is that the 
ADP-Glo™ assay is indeed suitable for use with our kinase of interest, TSSK1, even at 
low concentrations, making the feasibility of HTS and the possibility of screening a few 
thousand inhibitors against TSSK1 a certainty. As mentioned previously, the details 
outlined by Brooks, among others, indicate the numerous steps that must be taken prior to 
HTS to optimize the chances of finding the desired outcome – which in this case is a 
TSSK1 kinase inhibitor suitable for drug development (Brooks 2012). Based on the 
assays performed, nearly all required steps were met: all reagents were acquired, 
instrumentation was arranged, the assay concept was corroborated (see initial figures for 
this chapter), and the assay itself was optimized and validated. 
 One of the first steps of narrowing inhibitor choices was undertaken during this 
project. By testing the activity of TSSK1 against a variety of inhibitors in our mid-
throughput screening assay, results indicated significant inhibition in comparison to the 
control. As discussed, one such inhibitor showing promise was Compound C (CC). 
Although SKI-606 showed a comparable inhibitory effect, since it was a broad kinase 
inhibitor of Src and tyrosines, it was agreed that a more specific inhibitor should be 
investigated. Besides the evidence the assay provided, the several sources of literature 
indicated that CC was a potent, selective, and potentially reversible inhibitor of AMPK 
(Zhou, Myers et al. 2001, Hurtado de Llera, Martin-Hidalgo et al. 2012, Liu, Chhipa et al. 
2014, Nguyen, Alves et al. 2014).  
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  One clear observation was that both CC (a known serine/threonine kinase 
inhibitor) and SKI-606 (a known tyrosine kinase inhibitor) could be equally inhibiting 
TSSK1 activity. This fact, which had been also considered among the expected outcomes 
of testing such small battery of inhibitors, indicated that it is highly unlikely that CC was 
specific enough for further use in drug design against TSSK1 activity. However, the 
study was continued using this kinase inhibitor as a good indicator of potent TSSK1 
inhibition in vitro, and paved the way for in vivo studies. Also, because these assays were 
conducted prior to performing in vivo work, and because there was no strong evidence in 
the literature on the absence or presence of AMPK in mouse sperm, there was no way to 
know if CC was inhibiting AMPK or TSSK1. However, data presented here (best 
depicted in Figure 13) clearly supports the notion that CC can inhibit TSSK1 in vitro, 
even at very low concentrations.   
Due to its efficacy in vitro, in vivo assays were pursued, and the CC effect studied 
in mature mouse spermatozoa. However, caution was taken when considering the 
molecule as an in vivo inhibitor as per warnings found in Liu et al., which stated their 
lack of confidence in CC being a selective inhibitor of AMPK. But, because Liu did not 
perform in vitro studies on their cell line, it was decided to be a strong rationale for 
pursuing our analyses in vivo.  
The chief findings of these studies included (a) a very low abundance (if present) 
of AMPK in murine sperm; (b) the initial placement of a Compound C-sensitive kinase, 
which we hypothesize to be TSSK1, in the sperm biochemical pathway conducive to 
capacitation; (c) the effects of CC on sperm motility, viability, and acrosome reaction; 
and (d) the effect of CC in the fertilization process. Extensive literature searches were 
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performed to look into the presence or absence of AMPK in mouse sperm, although there 
is scarce published data on the subject, at least for the mouse model. As discussed in the 
Results section, we were able to detect a faint signal that was barely detectable following 
a long exposure in a Western blot probed with a monoclonal antibody. To increase the 
chances of detecting mouse sperm AMPK –by concentrating the sperm sample –an IP 
was performed, and despite multiple attempts with both poly- and monoclonal antibodies 
against alpha-AMPK, the catalytic subunit of AMPK, and use of both IgA and IgG beads, 
no murine signal was produced on the corresponding Western blot. These findings 
indicate that while there may be AMPK present in mouse sperm, it is at an extremely low 
concentration, which is in agreement with recent data by another lab using a different set 
of antibodies (Tartarin, Guibert et al. 2012). With this new insight, and under the 
presupposition that there are likely almost undetectable levels of AMPK in mouse sperm, 
the small-molecule inhibitor, CC was investigated in known sperm signaling pathways. 
As displayed in Figure 3, there are well-defined biochemical pathways in mature 
spermatozoa that are activated during capacitation (Visconti 2009). In our studies, as 
shown in Figure 15, a concentration curve of CC did not show any obvious change in the 
levels of phosphorylated PKA substrates, typically used as an indicator of PKA 
activation. In contrast, PY signaling was impacted. These findings would suggest that 
TSSK1 may be signaling upstream of PY, and thus PY-dependent phosphorylation (but 
not PKA), would be inhibited by Compound C. Alternatively, although not well 
understood at this time, a role for TSSK1 autophosphorylation in this cascade of events 
cannot be ruled out. According to early studies by Kueng et al. (1997) and others, and 
also based on in vitro data presented in this Thesis (Figure 9), TSSK1 is able to undergo 
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autophosphorylation (Kueng, Nikolova et al. 1997, Jaleel, McBride et al. 2005, 
Spiridonov, Wong et al. 2005). In this regard, TSSK1 autophosphorylating activity could 
be altered by CC, thus affecting signaling events related to sperm capacitation.  
The next conclusion was on the effect of Compound C on the occurrence of sperm 
spontaneous AR. As discussed in the Introduction section of this Thesis, the current 
model proposes that the acrosome reaction occurs when the sperm fuses with the oocyte 
and the enzyme-containing pocket is released. In this study the effect of CC increased the 
rate of AR. This indicated that instead of inhibiting the AR, some kinase(s) was being 
activated upon treatment with CC. It is interesting to note that our results, looking into 
the occurrence of spontaneous AR, contradict observations by other authors in boar 
sperm: according to the only source we found that investigated the effects of CC on 
mammalian sperm AR, the ionophore-induced AR is not affected by CC (Hurtado de 
Llera, Martin-Hidalgo et al. 2013). However, another source examined the effects of CC 
on oocytes in mice, and found that the AMPK inhibitor produced an opposite effect, 
stating that CC “increased the frequency of oocyte activation” (Downs, Ya et al. 2010, 
Acton 2012). The findings by Downs, et al. are very informative because although it was 
found in a different cell type, they too experienced an opposite effect than predicted. Our 
data also shows that the effect of CC on AR can reach levels as high as those found when 
AR is induced by a calcium ionophore (Figure 17).  
Performing a concentration curve with CC and subjecting the sperm to CASA 
analysis showed a severe decline in sperm motility. Consistent with recent studies by 
three independent research groups –Hurtado de Llera, Nguyen and Tartarin –who have 
investigated the effects of CC on boar, chicken, and mouse spermatozoa, respectively –
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CC has shown inhibitory effects on sperm motility and hyperactivation. Since the present 
project also examined viability in parallel to CASA experiments, it was also confirmed 
by the aforementioned sources that viability decreased only when exposed to the inhibitor 
for either an extended period of time, or to high concentrations (100uM or higher). It is 
important to note that an area requiring additional research is the reversibility of CC in 
relation to sperm motility. As discussed in the Results section, we performed a series of 
tests to address this question; however we were unable to detect clear signs of recovery 
on motility in sperm that had been exposed to CC. 
 The critical final step of evaluating the effect of CC on spermatozoa was to test its 
effect on fertilization. Compound C induced significantly decreased rates of fertilization 
in mice, similar to the decreased rates of fertilization of Tartarin et al. (Tartarin, Guibert 
et al. 2012). This is the true test of inhibitor potency since it is considered the most 
relevant functional endpoint to the process of contraceptive development. Thus far, no 
other studies have been performed using CC on IVF. It was interesting and somewhat 
unexpected that IVF using sperm pre-incubated with 30μM CC was able to fertilize as 
much as it did; the CASA data indicated that although there was only ~20% sperm 
motility, there was less than 5% of hyperactivity. As discussed previously, sperm must 
achieve hyperactivity prior to fertilization. With such low percentages of motile, 
hyperactive sperm, it seemed unlikely that many oocytes could have been fertilized. 
However our data shows that the opposite may be true. Ideally, additional experiments, 
such as using a wider range of CC concentrations, could be performed. IVF tends to be a 
costly experiment in terms of time and lab resources, including male and female mice. 
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4.2. Future Directions 
 The remaining steps necessary for commencing HTS using TSSK1 on a larger set 
of kinase inhibitors library is beyond the scope of this project. Following the experiments 
performed, in the case of our lab, collaborations with the HTS Facility at UMass 
Worcester have been recently established to pursue such goal. Leaving aside the financial 
aspect that accompanies any project needing to utilize a specialty Facility, inhibitors must 
be selected based on the biochemical properties of the intended target. Although there 
have been preliminary steps taken toward creation of a biased library of a few thousands 
of inhibitors, the protocols are still underway. Additionally, a few biochemical 
parameters remain to be determined or calculated for TSSK1, such as the IC50 of the 
kinase (one experiment has been performed to generate an approximate calculation, but 
more replicates are necessary); establishment of a crystal structure of TSSK1 would be 
ideal to have. Our group is currently working on 3-D models of TSSK1, which should 
help on a more rationale design of a TSSK1-focused screening of kinase inhibitors by 
HTS.  
 In terms of our in vivo findings, many of the next steps needed for this project lie 
within the ability to detect the presence of AMPK in mouse sperm. Additional 
experiments should be devised towards detecting the regulatory subunits of AMPK in 
sperm, for instance, using antibodies against AMPKβ and/or AMPKγ. Since AMPKα is 
the catalytic subunit, it seemed reasonable to test that specific subunit first. However, 
since it produced results that may be taken as contradictory, to some degree, when 
compared to published data on sperm from other species, testing the other two component 
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subunits of the AMPK complex would make for a more complete and thorough 
investigation of the presence or absence of AMPK in murine sperm. 
 To definitively test whether or not PKA is affected by CC, a radioactive kinase 
assay should be performed. Using P32 ATP, the activity of PKA’s ability to phosphorylate 
the substrate Kemptide under conditions including CC could be quantitatively measured.
 Further experiments in the realm of the acrosome reaction should be performed. 
As mentioned, the results that CC activated the AR were unexpected; if new experiments 
were performed and the results comparable, then it could be confirmed that CC indeed 
increases the rate of AR. However, further investigation into the biochemical reasoning 
for this occurrence would have to take place as well. Currently there is no evidence as to 
why or how this could happen so the biochemical aspect would have to be taken into 
consideration. Although it would take a great deal of time to optimize the conditions, 
fluorescence activated cell sorting (FACS) is another option for analysis. Once the 
parameters were established, FACS would be a way to quickly determine whether or not 
a cell had released its acrosome contents and the data could be plotted for analysis. 
 Additional experiments to investigate whether or not sperm can regain motility 
and/or achieve a hyperactive state following exposure to CC would be another area where 
more research is needed. Several sources indicate that CC should be a reversible 
inhibitor, however our attempts in this area have indicated otherwise. An interesting 
experiment to look into this issue would be to perform an IVF experiment and then wash 
the oocyte/cumulus cells/sperm cell complex following the 4 hour incubation and see if 
replacing the media would allow sperm to regain its fertilization ability. 
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 In summary, we have been able to further validate the use of a homogeneous 
kinase assay to assess TSSK1 activity in vitro, and have found experimental conditions 
for screening of large libraries of TSSK1 inhibitors by HTS. Furthermore, we have 
applied several functional in vivo assays for validating such inhibitor(s) as potential 
blocker(s) of TSSK1 function. In addition, we provide here valuable information on 
AMPK being present at very low levels in mouse sperm when compared to data provided 
by other authors who have analyzed the role of CC on the AMPK pathway in other 
species. Finally, we have documented very important observations on the effect of 
Compound C (also known as dorsomorphin or BML-275) on sperm signaling pathways 
conducive to its fertilizing ability. Overall, this Thesis provides strong support on TSSK1 
as a potential target for development of male contraceptives, as well as several rationale 
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